Drug Trial Radar · NCT01473524
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Last checked: Nov 19, 2026Latest source record: May 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
217
Actual
Start
Jan 2012
Primary completion
Dec 2013
Study completion Dec 17, 2018
Sponsor
- Lead sponsor
- Intercept PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objectives of the study were to assess the effects of Obeticholic Acid (OCA) on serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint and on safety in participants with primary biliary cirrhosis (PBC).
Conditions
- Primary Biliary Cirrhosis
Interventions
Obeticholic Acid (OCA)Drug
OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.
PlaceboDrug
Matching placebo tablets were administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus PlaceboTime frame: DB Month 12
- LTSE Phase: Composite Endpoint ALP And Total BilirubinTime frame: Baseline (DB Month 12), LTSE Months 24, 36, 48, and 60
Locations
59 sites in 13 countries. Site status is shown where the registry gives one.
UC Davis Medical Center
Sacramento, California
Scripps Clinic
San Diego, California
University of Colorado, Denver
Aurora, Colorado
University of Chicago
Chicago, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
Henry Ford Health System
Detroit, Michigan
St. Louis University
St Louis, Missouri
Beth Israel Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
Baylor College of Medicine
Houston, Texas
Liver Institute of Virginia
Newport News, Virginia
Liver Institute of Virginia
Richmond, Virginia
Virginia Commonwealth University/McGuire DVAMC
Richmond, Virginia
Swedish Medical Center
Seattle, Washington
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Austin Hospital
Heidelberg, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Medizinische Universität Innsbruck
Innsbruck, Austria
Medizinische Universität Wien
Vienna, Austria
UZ Leuven
Leuven, Belgium
Toronto Western Hospital Liver Centre
Toronto, Ontario, Canada
CHUM Hôpital St-Luc
Montreal, Quebec, Canada
Hopital Haut-Leveque
Pessac, France
Universitätsklinikum Aachen
Aachen, Germany
Friedrich-Alexander-Universität Erlangen
Erlangen, Germany
Klinikum der Johann-Wolfgang Goethe Universität Frankfurt am Main
Frankfurt am Main, Germany
Universitätsklinikum Hamburg Eppendorf
Hamburg, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Medizinische Universitätsklinik
Heidelberg, Germany
Gastroenterologische Gemeinschaftspraxis, Dres. Felten / Hartmann / Hüppe
Herne, Germany
Universitätsklinikum des Saarlandes
Homburg, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
LMU Klinikum der Universität München
München, Germany
Dip. Medicina Clinica - Università di Bologna
Bologna, Italy
Dip. Medicina Clinica- Università di Bologna
Bologna, Italy
Azienda Ospedaliera di Padova - Gastroenterologia
Padova, Italy
Istituto Clinico Humanitas
Rozzano (MI), Italy
VUmc Amsterdam
Amsterdam, Netherlands
AMC Amsterdam
Amsterdam, Netherlands
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.